Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

MoneyGroupLLC Jan. 21 at 8:38 PM

Enter: $ABBV Calls Strike Price: $215 Expiry Date: FEB 13 2026 Buy in Price: $6.79 - $7.13 Sell Price: $9.98 Profit : +47% (Turn every $1 into $1.47) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

FlaMeZ907 Jan. 21 at 8:24 PM

$ABBV Trump Already Chickened Out again. 🌮 Just like we predicted yesterday. They use that excuse to make a bear flag splash in your account and flip your positions around. They raked another 316 out of my account with this scam today.

0 · Reply

profit_guru Jan. 21 at 7:48 PM

$ABBV - might close above 220 if the rally continues as peers like $AMGN $LLY rallying due to rotation into healthcare stocks😊

0 · Reply

profit_guru Jan. 21 at 7:12 PM

$ABBV - final hour back to high of the day…typical pattern of this well run company…might see new 52 wk high after earnings…near term 240

0 · Reply

profit_guru Jan. 21 at 7:00 PM

$ABBV - whole health care rallying …expect strong rally into close as usual…might close above 220 $AMGN $LLY

0 · Reply

Gps_100X_ROI_Potential Jan. 21 at 6:58 PM

$SLS Simple Buy and Hold for the Gold. Gps P3 results are Coming - and they are worth 40B + to Big Pharma. $ABBV $BMY $RHHBY KNOW - Aza+VEN - the Best Available Treatment (BAT) for SLS P3 Control Arm Patients FAILED 4 Large Phase 3 Trials for AML Patients: - VIALE-C Failed to reach primary End Point - VIALE-M FAILED in CR1 Maintenance - VIALE-T FAILED post Transplant Maintenance - VERONA - Failed High Risk MDS/ AML Precursor meanwhile we are seeing Near Miraculous All pooled Data in the SLS P3.

0 · Reply

maikl_211 Jan. 21 at 6:23 PM

$PLTR $COST $NFLX $BAC $ABBV Polestar. This opportunity is here to stay. This company will have a very significant impact in the future, and you'll remember what I'm saying. It's the only company, along with Tesla, that specializes in electric vehicles. While Tesla produces low-quality, cheap plastic products, patience and more investment are key. Polestar manufactures in China, Europe, Korea, and the United States, and is expanding globally, already holding a market share.

0 · Reply

Gps_100X_ROI_Potential Jan. 21 at 4:08 PM

$SLS -- Look at what's happened - Since the IDMC UNBLINDED Actual Phase 3 Survival and Immune Response Data from theINTERIM ANALYSIS. - $ABBV $BMY $RHHBY Know Precisely how their drugs VEN + Aza ( CONTROL ARM BAT ) Perform in this CR2 Maintenance Trial - having failed the VIALE-M CR1 Phase 3 Maintenance trial. - only idiot retail don't know. - from just 39, up to 156 Institutional Funds invested - market cap up to $680M from just $77M - SLS increased +800% in Market Value - SLS Share Price Up over 300% - SLS Cash on Hand from just $13.8M to $98.4M right now - Runway into 2028 99.01 to .09 call to put ratio. - up to 49M Short - as of Dec 31. 28.8% - 12 days on the REGSHO FED WATCH LIST - AzaVEN Failed 3 Large Trials Since then too. - only idiot retail investors are getting fleeced by the lying short scammers. GPS Phase 3 Results are Coming and they are worth 70X the current Share Price. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

Guntz Jan. 21 at 4:02 PM

$ABBV Let's go. Give me another 1 percent!

0 · Reply

SuperGreenToday Jan. 21 at 1:47 AM

$ABBV Share Price: $213.98 Contract Selected: Feb 13, 2026 $215 Calls Buy Zone: $5.14 – $6.35 Target Zone: $8.21 – $10.03 Potential Upside: 51% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:35 PM EST - 5 days ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Jan 14, 2026, 5:45 PM EST - 7 days ago

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:01 PM EST - 7 days ago

AbbVie plans to build out its presence in obesity market

Jan 13, 2026, 7:22 AM EST - 9 days ago

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 5:24 AM EST - 9 days ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 12, 2026, 7:03 PM EST - 9 days ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 6:57 PM EST - 9 days ago

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:30 PM EST - 9 days ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 10 days ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 10 days ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 10 days ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 10 days ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Jan 12, 2026, 5:12 AM EST - 10 days ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

Jan 10, 2026, 9:30 AM EST - 11 days ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

Jan 8, 2026, 12:07 PM EST - 13 days ago

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 7:38 AM EST - 14 days ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

Jan 7, 2026, 2:58 PM EST - 14 days ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

Jan 7, 2026, 2:48 PM EST - 14 days ago

AbbVie Near Deal for Revolution Medicines

RVMD

Jan 7, 2026, 8:00 AM EST - 15 days ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 6, 2026, 11:43 AM EST - 15 days ago

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 7:29 AM EST - 16 days ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 17 days ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 4, 2026, 9:04 AM EST - 17 days ago

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 3, 2026, 7:30 AM EST - 19 days ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

Jan 1, 2026, 10:24 PM EST - 20 days ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Dec 31, 2025, 8:47 AM EST - 22 days ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 25 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Dec 19, 2025, 10:45 AM EST - 4 weeks ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 5 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 5 weeks ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

Dec 14, 2025, 11:30 PM EST - 5 weeks ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

Dec 10, 2025, 8:01 PM EST - 6 weeks ago

AbbVie: Unique Mix Of Growth And Value

Dec 8, 2025, 1:30 AM EST - 6 weeks ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 3, 2025, 4:53 PM EST - 7 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:15 AM EST - 7 weeks ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 1, 2025, 5:55 AM EST - 7 weeks ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Nov 29, 2025, 8:02 AM EST - 7 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

Nov 28, 2025, 7:01 AM EST - 7 weeks ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 25, 2025, 9:30 AM EST - 2 months ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 24, 2025, 8:00 AM EST - 2 months ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

Nov 18, 2025, 12:47 PM EST - 2 months ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 9:00 AM EST - 2 months ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

Nov 14, 2025, 4:31 PM EST - 2 months ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 3:19 PM EST - 2 months ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

Nov 13, 2025, 8:30 AM EST - 2 months ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 12, 2025, 3:06 PM EST - 2 months ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 8:30 AM EST - 2 months ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

MoneyGroupLLC Jan. 21 at 8:38 PM

0 · Reply

FlaMeZ907 Jan. 21 at 8:24 PM

0 · Reply

profit_guru Jan. 21 at 7:48 PM

$ABBV - might close above 220 if the rally continues as peers like $AMGN $LLY rallying due to rotation into healthcare stocks😊

0 · Reply

profit_guru Jan. 21 at 7:12 PM

$ABBV - final hour back to high of the day…typical pattern of this well run company…might see new 52 wk high after earnings…near term 240

0 · Reply

profit_guru Jan. 21 at 7:00 PM

$ABBV - whole health care rallying …expect strong rally into close as usual…might close above 220 $AMGN $LLY

0 · Reply

Gps_100X_ROI_Potential Jan. 21 at 6:58 PM

0 · Reply

maikl_211 Jan. 21 at 6:23 PM

0 · Reply

Gps_100X_ROI_Potential Jan. 21 at 4:08 PM

0 · Reply

Guntz Jan. 21 at 4:02 PM

$ABBV Let's go. Give me another 1 percent!

0 · Reply

SuperGreenToday Jan. 21 at 1:47 AM

0 · Reply

NickGurr69420 Jan. 21 at 12:25 AM

$SLS 3B buyout incoming. 17.59$ price per share will be the agreement. No approved meds. Blinded study No revenue. $ABBV isnt buying anyone out too many billions. Will gladly take my 100k profit when the time comes. But please be realistic folks, its not gonna rocket to 50$...not with that market cap

6 · Reply

IN0V8 Jan. 20 at 9:52 PM

$ABBV Opportunity Berenberg raises target price to $275 from $270

0 · Reply

cb5000calls Jan. 20 at 9:16 PM

$SLS There's a major reason why $ABBV discontinued their NCT04161885 (VIALE-T) trial (AbbVie; venetoclax + azacitidine maintenance after allo-SCT in AML). "Strategic Reasons".... buyout cough cough buyout!!! AbbVie’s termination of VIALE-T for strategic reasons underscores how challenging post-transplant maintenance has been for traditional drug regimens. While REGAL targets a different AML population, the contrast highlights why low-toxicity, immune-based maintenance strategies like GPS may ultimately prove more durable.

1 · Reply

profit_guru Jan. 20 at 8:35 PM

$ABBV - any analyst upgrade this will fly above 230…imo

0 · Reply

taxplanr Jan. 20 at 6:36 PM

$ABBV that gap cover could be last chance to get out or add to shorts

2 · Reply

Guntz Jan. 20 at 6:23 PM

$ABBV Big buys coming in. Last 1 min candle was 53k volume.

1 · Reply

profit_guru Jan. 20 at 5:51 PM

$ABBV - rotation from tech to healthcare going on…expect strong rally into close…near term 240…strong revenue growth, dividend…imo

0 · Reply

Gps_100X_ROI_Potential Jan. 20 at 4:26 PM

$SLS $ABVX https://x.com/nasa/status/2012684547419193794?s=46 Artemis II the Space Launch System (SLS) Rocket and Orion Spacecraft are on the Launch Pad. Seems Like $ABBV Buys SLS009 and $MRK Buys GPS

0 · Reply

Guntz Jan. 20 at 2:43 PM

$ABBV PT upgrade. Hopefully ends green

0 · Reply

Quantumup Jan. 20 at 12:23 PM

Guggenheim⬆️Best Idea $RVMD's PT to $160 from $92 and reiterated at a Buy $ABBV $MRK ERAS BBOT AMGN BMY RHHBY LLY IMRX Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2013587465387315204?s=20

0 · Reply

Badnanny Jan. 20 at 8:22 AM

$ABBV INTS-This has got to be worth a punt. So much potential, and Zacks ranking 2-buy.

0 · Reply

Market Cap	378.29B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	22.68
Forward PE	14.83
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	10,727,100
Avg Vol	6,155,030
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	29%
Beta	0.36
Analysts	Strong Sell
Price Target	$245.52